Imaging the Dopamine Systems in Bulimia Nervosa
This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:
NCT01493362
First received: December 14, 2011
Last updated: NA
Last verified: November 2011
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will use positron emission tomography imaging to investigate the dopamine systems in people with bulimia nervosa.
| Condition |
|---|
|
Eating Disorders |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | Imaging the Dopamine Systems in Bulimia Nervosa |
Resource links provided by NLM:
Further study details as provided by National Institute of Mental Health (NIMH):
Primary Outcome Measures:
- D2 receptor density [ Time Frame: Measured at baseline ] [ Designated as safety issue: No ]
- DA release in the striatum [ Time Frame: Measures after Mythlyphenidate challenge ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | January 2008 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
Participants with Bulimia Nervosa
|
|
2
Participants who are healthy controls
|
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
The study population will include people with bulimia nervosa seeking inpatient or outpatient treatment and people who will act as healthy control participants
Criteria
Inclusion Criteria:
Participants with BN:
- Meets DSM-IV criteria for BN
- Sufficiently medically and psychiatrically stable to participate in research
Health Control Participants:
- No current or past psychiatric illness
- Between 80% and 120% of ideal body weight
Exclusion Criteria:
All participants:
- Current use of psychotropic medication such as anti psychotics or antidepressants
- Pregnant or breastfeeding
- history of substance abuse
- Significant medical illness
- High blood pressure (resting systolic blood pressure greater than 150mmHg and diastolic blood pressure greater that 90 mmHg)
- Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder as defined by DSM-IV
- Metal implants or paramagnetic objects contained within the body that may interfere with the MRI scan, as determined in consultation with a neuroradiologist and according to specified reference book guidelines
- Exposed to radiation in the workplace or has had a nuclear medicine procedure during the 1 year before study entry
- Previous adverse reaction to psycho stimulants
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | National Institute of Mental Health (NIMH) |
| ClinicalTrials.gov Identifier: | NCT01493362 History of Changes |
| Other Study ID Numbers: | R01MH079397 |
| Study First Received: | December 14, 2011 |
| Last Updated: | December 14, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute of Mental Health (NIMH):
|
Bulimia Nervosa PET Imaging Dopamine |
Additional relevant MeSH terms:
|
Bulimia Eating Disorders Bulimia Nervosa Hyperphagia Signs and Symptoms, Digestive Signs and Symptoms Mental Disorders Dopamine Dopamine Agents Cardiotonic Agents |
Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on May 21, 2013